Rosarin

Rosarin at a Glance

Rosarin is a cinnamyl alcohol glycoside of Rhodiola rosea (roseroot) and one of the three “rosavins” — the co-marker set (with rosavin and rosin) that is characteristic of R. rosea and used to authenticate the herb against cheaper Rhodiola species ^{1,2Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}. It is best understood as rosavin’s sugar isomer: the two molecules share the same cinnamyl-glucoside core and differ only in the ring form of an added arabinose (see below).

This is a deliberately lean page, because rosarin is a genuinely thin molecule. Almost no work has tested purified rosarin on its own — its documented role is analytical (a standardisation and authentication marker), and the adaptogenic, anti-fatigue and antioxidant reputation attached to “the rosavins” belongs to the whole standardised extract, driven mainly by salidroside and the rosavins fraction together ^{2,3Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →}. Rather than restate that pharmacology here, the detail sits on the rosavin and salidroside pages, where the extract-level evidence is handled.

Rosarin, Rosavin & the Rhodiola Rosavins

The “rosavins” are a small family of cinnamyl alcohol glycosides that are largely unique to Rhodiola rosea, which is why the genus is standardised on them: their presence — and the roughly 3:1 rosavins-to-salidroside ratio — distinguishes authentic R. rosea from cheaper species such as R. crenulata that carry salidroside but little of the rosavins ^{1,2Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}.

The three co-markers are built one sugar at a time from the same starting point ^{4Reference 4Bi H et al. · 2022Biosynthesis of a rosavin natural product in Escherichia coli by glycosyltransferase rational design and artificial pathway constructionView study →}:

Marker	Structure	Relationship
Rosin	Cinnamyl alcohol + one glucose (the simplest cinnamyl monoglucoside)	The shared parent
Rosavin	Rosin + an arabinopyranose	The principal, most abundant rosavin
Rosarin	Rosin + an arabinofuranose	Rosavin’s isomer — same sugars, different ring form

So rosarin differs from rosavin by a single detail: the added arabinose closes as a five-membered furanose ring in rosarin versus a six-membered pyranose ring in rosavin ^{1,4Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →Reference 4Bi H et al. · 2022Biosynthesis of a rosavin natural product in Escherichia coli by glycosyltransferase rational design and artificial pathway constructionView study →}. They are otherwise the same diglycoside of cinnamyl alcohol. Commercial R. rosea extract typically reports rosavin as the largest of the three, with rosin and rosarin present at lower, variable levels — which is one reason rosarin has rarely been isolated and studied alone.

What It's Used For

Rosarin has essentially no isolate-specific pharmacology of its own. Its documented function is as a marker; its presumed bioactivity is inferred from the rosavins group and the whole extract.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. This molecule is thin and mostly studied as part of a group, so scores are low by design; read the per-row basis.

01Analytical marker / authenticationShaky40%Validated HPLC marker for R. rosea quality control ^{1,2Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}

02Adaptogenic / anti-fatigue (rosavins group)Shaky22%Whole standardised extract, not the isolate ^{2,3Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →}

03Antioxidant (group / in vitro)Shaky16%Rosavins-fraction / extract assays; rosarin one contributor ^{3Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →}

Mechanisms

The load-bearing point is honesty: only the marker role is demonstrated for rosarin itself. The signalling row is a pointer to the extract’s pharmacology, not a claim that purified rosarin drives it.

Pharmacokinetics

There are no rosarin-specific human pharmacokinetic data. As a polar cinnamyl diglycoside, rosarin would be expected to be poorly absorbed intact and subject to gut-microbial deglycosylation — the general pattern for glycosidic rosavins — but this has not been characterised for rosarin as an isolate. Pharmacokinetic study in R. rosea has centred on salidroside (and its aglycone tyrosol) and on rosavin; rosarin is measured analytically for content, not tracked in plasma ^{1Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →}. The practical implication: any systemic activity attributed to rosarin is unverified, and the compound is consumed only as a minor part of a whole extract.

Clinical Trials

There are no clinical trials of isolated rosarin. Human evidence in this area is for standardised R. rosea extract (dosed by salidroside/rosavins content), reviewed at the herb and rosavin pages ^{2Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

Rosarin sits almost entirely on the plant/extract side of this divide. The only thing consistently done with purified rosarin is to detect and quantify it as a marker ^{1Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →}; it has not been the subject of a controlled bioactivity study on its own. Every adaptogenic, anti-fatigue or antioxidant claim in its vicinity comes from whole standardised R. rosea extract or the rosavins fraction, where salidroside and rosavin are the better-characterised actives and rosarin is a minor co-occurring glycoside ^{2,3Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →}. This is the honest reason the page is short: attributing the extract’s effects to rosarin specifically would over-reach the evidence.

Prevalence in Nature

Rosarin is a minor cinnamyl glycoside of Rhodiola rosea rhizome and root, one of the “rosavins” that are largely restricted to this species and therefore used to authenticate it ^{1,2Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}. Within the ~3% rosavins fraction of a standardised extract, rosavin usually predominates, with rosin and rosarin present at lower and more variable levels ^{2Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}.

Biosynthetically, the rosavins are phenylpropanoid products of L-phenylalanine: rosin is formed by glucosylating cinnamyl alcohol (the simplest cinnamyl monoglucoside), and rosarin and rosavin arise from rosin by adding an arabinose — as the furanose form in rosarin and the pyranose form in rosavin ^{4Reference 4Bi H et al. · 2022Biosynthesis of a rosavin natural product in Escherichia coli by glycosyltransferase rational design and artificial pathway constructionView study →}. The full R. rosea rosavin pathway has not been completely elucidated, though the glucosylation step and the rosin intermediate are established, including in engineered systems ^{4Reference 4Bi H et al. · 2022Biosynthesis of a rosavin natural product in Escherichia coli by glycosyltransferase rational design and artificial pathway constructionView study →}.

Discovery & Synthesis

Rosarin was not the subject of a single discovery paper so much as it emerged from the mid-to-late twentieth-century phytochemical mapping of Rhodiola rosea, and it was placed firmly into routine quality control by the HPLC marker methods of the early 2000s that resolved salidroside, rosavin, rosin, rosarin and rosiridin together ^{1Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →}. Chemically it is defined by its structure — the arabinofuranosyl isomer of rosavin — rather than by an isolation milestone.

There is no established stand-alone synthesis or commercial manufacture of rosarin: it is not sold as an isolated ingredient but obtained (and standardised) only within R. rosea extract. The related biosynthetic chemistry — glucosylation of cinnamyl alcohol to rosin, then arabinosylation to the rosavin isomers — has been reconstructed in engineered microbes for the rosavin branch, and the same logic applies to the arabinofuranosyl (rosarin) branch ^{4Reference 4Bi H et al. · 2022Biosynthesis of a rosavin natural product in Escherichia coli by glycosyltransferase rational design and artificial pathway constructionView study →}.

Patents: not yet researched.

Toxicity & Safety

Rosarin carries a low flag. There is no isolate-specific toxicology for it — no genotoxicity, repeat-dose or reproductive dataset for the purified compound — and its only meaningful human exposure is as a minor constituent of standardised R. rosea extract, a preparation with a long record of human use and a generally favourable safety profile at customary doses ^{2Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}. As a simple cinnamyl diglycoside present at low levels, it has no specific hazard signal of its own; the honest position is that safety here is inherited from the extract, not demonstrated for the isolate.

Safety at a Glance

✅ Low / no toxicity

• Low isolate-toxicity signal. No organ-, geno- or reproductive-toxicity finding specific to purified rosarin; consumed only within R. rosea extract.
• Favourable extract record. Standardised R. rosea extract has a long history of human use with good tolerability at customary doses ^{2Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}.
• Safety is inherited, not proven for the isolate. No dedicated toxicology exists for pure rosarin — absence of a hazard signal is not the same as tested safety.
• Species discipline matters. Adaptogenic/safety data belong to authentic R. rosea (rosavins-bearing); other Rhodiola species have different profiles and should not be pooled ^{1Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatographyView study →}.
• Pregnancy/lactation is decided at the herb level. No isolate reproductive data; those decisions belong on the Rhodiola herb and product pages, not this molecule page.

Dosage

There is no isolated rosarin dose — it is not sold or used as a stand-alone ingredient. Human exposure is entirely as a minor component of standardised R. rosea extract, which is dosed by its salidroside and rosavins content, not by rosarin. Typical research and commercial preparations are standardised to roughly ~3% rosavins and ~1% salidroside (the ~3:1 target that mirrors the root), at extract doses commonly in the range of a few hundred milligrams per day ^{2Reference 2Panossian A et al. · 2010Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacyView study →}. These are extract-standardisation figures, not a recommendation for the isolate — for dosing detail, see the Rhodiola herb page and the rosavin and salidroside pages.

References

1. Ganzera M, Yayla Y, Khan IA (2001). Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase high performance liquid chromatography. Chemical & Pharmaceutical Bulletin (Tokyo). https://pubmed.ncbi.nlm.nih.gov/11310675/
2. Panossian A, Wikman G, Sarris J (2010). Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/20378318/
3. Wang S, Feng Y, Zheng L, He P, Tan J, Cai J, Wu M, Ye X (2023). Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea L. Molecules. https://pubmed.ncbi.nlm.nih.gov/37959831/
4. Bi H, Qu G, Wang S, Zhuang Y, Sun Z, Liu T, Ma Y (2022). Biosynthesis of a rosavin natural product in Escherichia coli by glycosyltransferase rational design and artificial pathway construction. Metabolic Engineering. https://pubmed.ncbi.nlm.nih.gov/34715353/